Table 3.
Tumor volume in association with PFS
| HR (95% CI) | P-value | |
|---|---|---|
| Total volume (per 100 cm3) | 1.1 (0.9, 1.3) | 0.47 |
| Sex | 0.35 | |
| Male | 1.0 | |
| Female | 1.2 (0.8, 1.9) | |
| Age | 0.59 | |
| ≤59 yrs | 1.0 | |
| 60–69 yrs | 1.2 (0.7, 1.9) | |
| ≥70 yrs | 0.9 (0.5, 1.5) | |
| Primary | 0.94 | |
| Lung adeno | 1.0 | |
| Lung squam | 1.0 (0.7, 1.6) | |
| Lung poorly diff | 0.9 (0.2, 2.4) | |
| Best Responsea | <0.001 | |
| PR | 1.0 | |
| SD | 4.6 (2.3, 9.4) | |
| PD | 43.9 (17.9, 107.3) | |
| Metastasizes | 0.007 | |
| M0/M1a | 1.0 | |
| M1b | 1.0 (0.5. 2.3) | |
| M1c | 2.0 (1.3, 3.1) | |
| Previous lines of Tx | 0.005 | |
| 0 | 1.0 | |
| 1 | 2.4 (1.4, 4.3) | |
| 2 or more | 2.1 (1.1, 4.2) | |
| Agent | 0.006 | |
| Pembro | 1.0 | |
| Pembro + other | 1.0 (0.5, 2.1) | |
| Nivo | 2.0 (1.1, 3.8) | |
| On protocol | 0.006 | |
| No | 1.0 | |
| Yes | 0.5 (0.3, 0.8) | |
| Hospitalization w/i 6 wka | 0.001 | |
| No | 1.0 | |
| Yes | 2.3 (1.4, 3.9) | |
| Reason for discontinuation | <0.001 | |
| PD, decline, PD-1 AE | 1.0 | |
| Completed Tx | 0.1 ((0.05, 0.4) | |
| Other | 0.4 (0.1, 1.2) | |
| Unmeasurable lung | 0.03 | |
| No | 1.0 | |
| Yes | 1.8 (1.0, 3.0) | |
| Unmeasurable LN | 0.55 | |
| No | 1.0 | |
| Yes | 0.9 (0.6, 1.3) | |
| Unmeasurable Liver | 0.06 | |
| No | 1.0 | |
| Yes | 1.7 (1.0, 2.8) | |
| Unmeasurable soft tissue | 0.41 | |
| No | 1.0 | |
| Yes | 1.2 (0.8, 1.9) | |
| Lung (per 100 cm3) >2 cm | 1.0 (0.8, 1.3) | 0.99 |
| LN (per 100 cm3) >1.5 cm | 0.8 (0.4, 1.7) | 0.59 |
| Liver (per 100 cm3) >2 cm | 2.6 (1.0, 7.0) | 0.11 |
| Soft tissue (per 100 cm3) >2 cm | 1.8 (1.1, 2.9) | 0.02 |
Notes: aFor those followed for at least weeks.
Abbreviations: AE, adverse events; SD, stable disease; PD-1, program death-1; PR, partial response; PFS, progression free survival; LN, lymph node; PD, progression of disease.